Choose Your News
Loading...
Thumbnail
Surgery Partners Inc (NASDAQ:SGRY) could really benefit from the aging population. The company is expected to ramp up its growth, which should translate into a... [Read More]
Thumbnail
Replimune is currently conducting a Phase 1/2 clinical trial to treat cancer. Initiation of Phase 2 clinical trial of RP1 with Regeneron is expected in... [Read More]
Preview